Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Gains from Sales and Divestitures (2019 - 2025)

Historic Gains from Sales and Divestitures for Eton Pharmaceuticals (ETON) over the last 6 years, with Q3 2025 value amounting to $84204.0.

  • Eton Pharmaceuticals' Gains from Sales and Divestitures fell 685.6% to $84204.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $84204.0, marking a year-over-year decrease of 685.6%. This contributed to the annual value of $90402.0 for FY2024, which is 109.41% down from last year.
  • Eton Pharmaceuticals' Gains from Sales and Divestitures amounted to $84204.0 in Q3 2025, which was down 685.6% from $889.0 recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $91402.0 in Q3 2023 and a low of $889.0 during Q2 2025
  • Over the past 4 years, Eton Pharmaceuticals' median Gains from Sales and Divestitures value was $90402.0 (recorded in 2024), while the average stood at $65185.1.
  • In the last 5 years, Eton Pharmaceuticals' Gains from Sales and Divestitures changed by 0.0% in 2021 and then crashed by 685.6% in 2025.
  • Eton Pharmaceuticals' Gains from Sales and Divestitures (Quarter) stood at $7595.0 in 2021, then soared by 1103.45% to $91402.0 in 2023, then fell by 1.09% to $90402.0 in 2024, then dropped by 6.86% to $84204.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $84204.0 for Q3 2025, versus $889.0 for Q2 2025 and $90402.0 for Q4 2024.